CTI ends Pixuvri's NICE saga on a high with U-turn recommendation
This article was originally published in Scrip
Executive Summary
Cell Therapeutics (CTI) has finally produced an analysis which has convinced NICE to recommend its non-Hodgkin's lymphoma drug Pixuvri (pixantrone), following repeated rejections from the institute since April 2013.